Î人´óѧµÄÑо¿ÈËÔ±ÔÚÐÂÑо¿ÖÐ֤ʵ£¬Ò»¸öÐÄÔ฻¼¯µÄ³¤·Ç±àÂ루lnc£©RNA¡ª¡ª±»³ÆÎªÐļ¡·ÊºñÏà¹Ø±í¹ÛÒÅ´«Ñ§µ÷½ÚÒò×Ó£¨Chaer£©£¬¶ÔÓÚÐļ¡·ÊºñµÄ·¢Õ¹ÊÇÖÁ¹ØÖØÒªµÄ¡£ÕâÒ»Ñо¿³É¹û·¢²¼ÔÚ9ÔÂ12Èյġ¶×ÔȻҽѧ¡·£¨Nature Medicine£©ÔÓÖ¾ÉÏ¡£

Áìµ¼ÕâÒ»Ñо¿µÄÊÇÎ人´óѧÐÄѪ¹Ü²¡Ñо¿Ëù¸±Ëù³¤ÀîºìÁ¼£¨Hongliang Li£©½ÌÊÚ£¬ËûÊǹú¼Ò½Ü³öÇàÄê»ù½ð»ñµÃÕß¡¢¡°****¡±ÌØÆ¸½ÌÊÚ¡¢ÈëÑ¡¿Æ¼¼²¿ÖÐÇàÄê¿Æ¼¼´´ÐÂÁì¾üÈ˲Å¡¢½ÌÓý²¿ÐÂÊÀ¼ÍÓÅÐãÈ˲żƻ®¡¢ºþ±±Ê¡¸ß¶ËÈ˲żƻ®¡££¨×îÐÂ****ÌØÆ¸½ÌÊÚ¹«Ê¾Ãûµ¥£¨ÉúÎïÀࣩ£»µÚ¶þÅú¹ú¼Ò¡°****¡±Áì¾üÈ˲ÅÃûµ¥¹«Ê¾£©¡£ÀîºìÁ¼½üÊ®ÓàÄêÀ´Ò»Ö±ÖÂÁ¦ÓÚÐÄѪ¹Ü´úлÐÔ¼²²¡µÄÑо¿,Î§ÈÆÌìÈ»ÃâÒßµ÷¿ØÍøÂç¶ÔÐÄѪ¹Ü´úлÐÔ¼²²¡µÄ×÷Ó㬽øÐÐÁËÉîÈëµÄÑо¿Óë̽ÌÖ£¬È¡µÃÁËһϵÁÐÖØÒªÑо¿³É¹û£¬·¢±í¹ú¼ÊÆÚ¿¯ÂÛÎÄ100ÓàÆª£¬·¢±íÂÛÎÄSCI×ÜÒýÓôÎÊý½ü3000´Î£¬²¢ÈëÑ¡2014¡¢2015ÄêÖйú¸ß±»ÒýѧÕß°ñµ¥£¨Ò½Ñ§£©¡£

ĿǰÐÄÄÔѪ¹Ü¼²²¡ÒѳÉΪΣº¦ÎÒ¹úÈËÃñÉíÌ彡¿µµÄ¡°Í·ºÅɱÊÖ¡±£¬ÒòÐÄÄÔѪ¹Ü¼²²¡ËÀÍöÈËÊýÕ¼×ÜËÀÍöÈËÊýµÄ±ÈÀý³ÊѸËÙÉÏÉýÇ÷ÊÆ£¬ÇÒÔ½À´Ô½Ç÷ÓÚÄêÇữ¡£²¡ÀíÐÔÐļ¡·Êºñ£¨pathological cardiac hypertrophy£©ÊÇÐí¶àÐÄѪ¹Ü¼²²¡Èç¸ßѪѹ¡¢¹ÚÐIJ¡¡¢°êĤ¼²²¡µÈÖÕÄ©ÆÚ¹²Í¬µÄ²¡ÀíÉúÀí±íÏÖ£¬ÏÖÓÐÑо¿ÒѾ­¹«Èϲ¡ÀíÐÔÐļ¡·ÊºñÊÇÐÄË¥µÄǰÆÚ²¡±ä£¬ÊÇÐÄË¥¡¢ÄÔ×äÖС¢¹ÚÐIJ¡¡¢â§ËÀµÈµÄ¶ÀÁ¢Î£ÏÕÒòËØ¡£

Ãâ·ÑË÷È¡¿µ³ÉÉúÎïlncRNAÑо¿ÁìÓòµÄ¼¼Êõ·þÎñ×ÊÁÏ

±í¹ÛÒÅ´«Öرà³ÌÊÇÐļ¡·ÊºñºÍÖØËܹý³ÌÖв¡ÀíÐÔ»ùÒòÓÕµ¼µÄÒ»¸ö¹Ø¼ü¹ý³Ì£¬µ«ÊÇDZÔڵĵ÷¿Ø»úÖÆÈÔÓдýÓÚ²ûÃ÷¡£ÔÚÕâÏîÑо¿ÖУ¬Ñо¿ÈËԱȷ¶¨ÁËÒ»¸öÐÄÔ฻¼¯µÄ³¤·Ç±àÂ루lnc£©RNA¡ª¡ª±»³ÆÎªÐļ¡·ÊºñÏà¹Ø±í¹ÛÒÅ´«Ñ§µ÷½ÚÒò×Ó£¨Chaer£©£¬¶ÔÓÚÐļ¡·ÊºñµÄ·¢Õ¹ÊÇÖÁ¹ØÖØÒªµÄ¡£´Ó»úÖÆÉÏÀ´¿´£¬ChaerÓë¶àÊáÒÖÖÆ¸´ºÏÎï2£¨pRC2£©µÄ´ß»¯ÑÇ»ùÖ±½ÓÏ໥×÷Óá£ÕâÖÖÏ໥×÷Óã¬ÊÇÓÉChaerÖеÄÒ»¸ö66-merµÄÐòÁн鵼µÄ£¬¸ÉÈÅÁËpRC2°ÐÏò»ùÒò×éλµã£¬´Ó¶øÒÖÖÆÁËÐļ¡·ÊºñÏà¹Ø»ùÒòÆô¶¯×ÓÇøÉϵÄ×éµ°°×H3Àµ°±Ëá27¼×»ù»¯¡£

ChaerºÍpRC2Ö®¼äµÄÏ໥×÷ÓÃÊÇÔÚÒ»¸öÉæ¼°²¸È鶯ÎïÀ×ÅÁÃ¹ËØ°Ðµã¸´ºÏÎï1µÄ¹ý³ÌÖУ¬ÔÚ¼¤ËØ»òÓ¦¼¤´Ì¼¤ºó˲ʱÓÕµ¼µÄ£¬ÕâÖÖÏ໥×÷ÓÃÊÇÐļ¡·ÊºñÏà¹Ø»ùÒòµÄ±í¹ÛÒÅ´«Öرà³ÌºÍÓÕµ¼µÄÒ»¸öÏȾöÌõ¼þ¡£ÔÚѹÁ¦¸ººÉ¿ªÊ¼Ö®Ç°¡ª¡ª¶ø²»ÊÇÖ®ºó£¬ÒÖÖÆChaerÔÚÐÄÔàµÄ±í´ï£¬¿É´ó·ù¶È¼õÇáÐļ¡·ÊºñºÍ¹¦ÄÜÕϰ­¡£ÕâÏîÑо¿±íÃ÷£¬Ñ¹Á¦ÓÕµ¼µÄ²¡ÀíÐÔ»ùÒòÔÚÐÄÔàÖб»¼¤»î£¬ÐèÒªÒ»¸öÒÔǰδ֪µÄlncRNAÏà¹Ø±í¹ÛÒÅ´«Ñ§¼ì²éµã¡£

ÕâÒѾ­ÊÇÀîºìÁ¼½ÌÊÚ½ñÄê·¢±íµÄµÚËÄÏîÑо¿³É¹û£¬2ÔÂ17ÈÕ£¬Ëû´øÀ´µÄÑо¿Ð¡×éÔÚ¡¶Nature Communications¡·ÔÓÖ¾·¢±íÂÛÎÄ֤ʵ£¬¸Îϸ°ûTRAF3ͨ¹ý°ÐÏòTAK1ÒÀÀµÐÔÐźŴٽøÁ˸ÎÖ¬·¾±äÐÔºÍÈ«ÉíÐÔÒȵºËصֿ¹¡£Ïà¹ØÔĶÁ£ºÎ人´óѧNature×Ó¿¯½Òʾ֬·¾¸Î²¡ÒòлúÖÆ¡£

6Ô·ݣ¬ÀîºìÁ¼½ÌÊÚÁìµ¼µÄÑо¿Ð¡×éÔÚ²¡ÀíÐÔÐļ¡·ÊºñµÄÑо¿ÖÐÈ¡µÃÖØ´óÍ»ÆÆ£¬Á½ÆªÑо¿ÂÛÎÄ·¢±íÔÚͬÈÕ£¨6ÔÂ1ºÅ£©µÄ¡¶×ÔȻͨѶ¡·£¨Nature Communications£©ÔÓÖ¾ÉÏ¡£Ïà¹ØÔĶÁ£ºÎ人´óѧͬÈÕ·¢±íÁ½ÆªNature×Ó¿¯ÎÄÕ¡£

£¨ÉúÎïͨ£ºÍõÓ¢£©

ÉúÎïÍ¨ÍÆ¼öÔ­ÎÄÕªÒª£º
The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy
Abstract: Epigenetic reprogramming is a critical process of pathological gene induction during cardiac hypertrophy and remodeling, but the underlying regulatory mechanisms remain to be elucidated. Here we identified a heart-enriched long noncoding (lnc)RNA, named cardiac-hypertrophy-associated epigenetic regulator (Chaer), which is necessary for the development of cardiac hypertrophy. Mechanistically, Chaer directly interacts with the catalytic subunit of polycomb repressor complex 2 (pRC2). This interaction, which is mediated by a 66-mer motif in Chaer, interferes with pRC2 targeting to genomic loci, thereby inhibiting histone H3 lysine 27 methylation at the promoter regions of genes involved in cardiac hypertrophy. The interaction between Chaer and pRC2 is transiently induced after hormone or stress stimulation in a process involving mammalian target of rapamycin complex 1, and this interaction is a prerequisite for epigenetic reprogramming and induction of genes involved in hypertrophy. Inhibition of Chaer expression in the heart before, but not after, the onset of pressure overload substantially attenuates cardiac hypertrophy and dysfunction. Our study reveals that stress-induced pathological gene activation in the heart requires a previously uncharacterized lncRNA-dependent epigenetic checkpoint.